Although most nephrologists spend their days managing patients with acute and chronic kidney disease (CKD), it is useful to occasionally consider the landscape of our current treatment approach. Here, we present the hypothesis that the major mechanisms that drive CKD are changing and will necessitate new approaches to manage this disease.
This is a preview of subscription content
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Mitch, W. E., Walser, M., Buffington, G. A. & Lemann, J. Jr. A simple method of estimating progression of chronic renal failure. Lancet 2, 1326–1328 (1976).
Mogensen, C. E., Christensen, C. K. & Vittinghus, E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32 (Suppl. 2), 64–78 (1983).
Polonia, J., Azevedo, A., Monte, M., Silva, J. A. & Bertoquini, S. Annual deterioration of renal function in hypertensive patients with and without diabetes. Vasc. Health Risk Manag. 13, 231–237 (2017).
Perera, G. A. Hypertensive vascular disease; description and natural history. J. Chron. Dis. 1, 33–42 (1955).
Eldredge, N. & Gould, S. J. in Models in Paleobiology (ed. Schopf, T. J. M.) 82–115 (Cooper and Co., 1972).
Stevens, P. E., Levin, A. & Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158, 825–830 (2013).
Research conducted in the authors’ laboratories is funded by grants from FONACYT, Venezuela (FC-2005000283, to BR-I) and Asociación de Amigos del Riñón (to BR-I) and by the National Institutes of Health NIDDK Institute (1RO1DK109408-01A1 and R01 DK108859-01).
R.J.J. is on the Scientific Board of XORT Therapeutics, has patent and patent applications related to lowering uric acid or blocking fructose metabolism in the treatment of hypertension and metabolic disorders, and is a member of Colorado Research Partners, LLC, which is developing inhibitors of fructose metabolism. B.R.I. declares no competing interests.
About this article
Cite this article
Johnson, R.J., Rodriguez-Iturbe, B. Rethinking progression of CKD as a process of punctuated equilibrium. Nat Rev Nephrol 14, 411–412 (2018). https://doi.org/10.1038/s41581-018-0016-4
Nature Reviews Nephrology (2019)